One subtype shows more pronounced neurological differences than the others
For generations, ADHD has been understood as a single condition wearing different masks — inattentive, hyperactive, or both — but new neuroimaging research suggests the disorder is not one thing at all. Scientists have identified three distinct subtypes, each with its own biological signature in the brain, including one that appears markedly more severe than the others. This discovery invites medicine to reconsider not just how ADHD is treated, but what it fundamentally is — a question with profound consequences for the millions who live inside its diagnosis.
- The long-held assumption that ADHD is a single condition with varying intensity is now being directly challenged by biological evidence from brain scans.
- One of the three newly identified subtypes shows significantly more extreme neurological differences, suggesting some patients may be carrying a far heavier burden than current frameworks acknowledge.
- Today's diagnostic process — built on behavioral checklists and symptom reports — may be too blunt an instrument to capture these distinct neurobiological realities.
- The mismatch between subtypes could explain why medications and behavioral therapies work dramatically for some patients and barely at all for others.
- Researchers and clinicians are now looking toward a future where a diagnosis names not just the condition, but the specific subtype — and points toward a tailored treatment path.
For decades, ADHD has been treated as a single disorder — patients might lean inattentive or hyperactive, but the underlying assumption was that the condition was fundamentally the same across individuals. New neuroimaging research is dismantling that premise. By examining patterns in brain structure and function, scientists have identified three distinct subtypes of ADHD, each with its own neurological signature. Crucially, one of these subtypes appears significantly more severe than the others, involving more pronounced differences in how the brain is organized.
This matters because it reframes ADHD not as a spectrum of one thing, but as a family of distinct conditions sharing a name. A treatment that works well for one subtype may offer little to another — which could explain the wide variation clinicians already observe in how patients respond to medication or behavioral intervention.
Currently, diagnosis depends almost entirely on behavioral observation and self-reported symptoms. Introducing biological markers into that process could sharpen accuracy, especially in cases where ADHD symptoms overlap with other conditions or present atypically. It could also give patients and clinicians a clearer map of what to expect and what to try.
The research is still early, and the road from laboratory finding to clinical practice is rarely short. But the implications are significant: a future ADHD diagnosis might specify not just that someone has the condition, but which form they have — and what that means for how they should be treated. For millions of people who have long felt that standard approaches never quite fit, that possibility carries real weight.
For decades, doctors have treated ADHD as a single condition with varying degrees of severity. A patient might be inattentive or hyperactive or both, but the underlying assumption remained constant: the disorder was fundamentally the same across individuals. New research using brain imaging is challenging that premise. Scientists have identified three distinct subtypes of ADHD, each with its own neurological signature, and one of them appears to represent a significantly more severe form of the condition.
The findings emerge from neuroimaging studies that examined the brains of people with ADHD, looking for patterns in structure and function that might distinguish one presentation from another. What researchers discovered was not a spectrum but rather distinct categories—different ways the brain can organize itself in ways that produce ADHD symptoms. This distinction matters because it suggests that not all ADHD is created equal, and that a treatment effective for one subtype might not work equally well for another.
One of the three subtypes identified in the research shows more extreme neurological characteristics than the others. This severe form appears to involve more pronounced differences in brain structure or function compared to the other two subtypes. The implications are significant: a person with this more severe presentation might require different intervention strategies, different medication approaches, or different expectations about treatment response than someone with a milder neurological variant.
The ability to distinguish between ADHD subtypes using brain imaging opens a new door in how the condition is diagnosed and managed. Currently, ADHD diagnosis relies primarily on behavioral observation and symptom reporting—a clinician listens to a patient's history and checks boxes on a rating scale. Adding biological markers to that process could improve diagnostic accuracy, particularly in cases where symptoms overlap with other conditions or where the presentation is atypical. It could also help explain why some people respond dramatically to medication while others see minimal benefit, or why certain behavioral interventions work for some patients but not others.
The research represents a shift in how neuroscience approaches neurodevelopmental disorders. Rather than viewing ADHD as a single condition with variable expression, this work suggests that the disorder itself comes in distinct forms, each rooted in different neurobiological mechanisms. Understanding these differences could eventually lead to more targeted, personalized approaches to treatment—matching specific interventions to specific subtypes rather than applying a one-size-fits-most model.
For the millions of people living with ADHD, and for the clinicians treating them, these findings suggest that the future of ADHD care may involve more precision. A diagnosis might eventually include not just confirmation that someone has ADHD, but specification of which subtype they have and what that means for their particular treatment path. The work is still in its early stages, and translating research findings into clinical practice typically takes time. But the door has opened to a more nuanced understanding of a condition that has long been treated as simpler than it actually is.
The Hearth Conversation Another angle on the story
So researchers found three types of ADHD using brain scans. What exactly were they looking at in the brain?
They were examining structural and functional differences—how the brain is organized and how different regions communicate. The idea is that ADHD isn't just a behavioral pattern; it has a biological foundation, and that foundation can take different forms.
And one of these three forms is more severe than the others?
Yes. One subtype shows more pronounced neurological differences. That's the key finding—it's not just that people have more or fewer symptoms, but that the underlying brain organization is fundamentally different in this group.
Does that change how doctors would treat someone?
Potentially, yes. Right now, treatment is mostly based on symptoms and trial-and-error. If you can identify which subtype someone has, you might be able to predict which treatments will actually work for them, rather than cycling through options.
Why has this taken so long to figure out?
Brain imaging technology has improved dramatically, and researchers are now able to see patterns they couldn't see before. Also, ADHD has been treated as a single condition for so long that the question of whether it might be multiple conditions didn't get asked as urgently.
What happens next?
The research needs to be replicated and expanded. Then clinicians need to figure out how to use this information in practice—how to scan brains, how to classify patients, how to match subtypes to treatments. It's a bridge between discovery and real clinical change.